Patient Characteristics (n = 37)
| Characteristic | Data |
|---|---|
| Age (y) | 70 (IQR, 61–74) |
| ISUP grade | |
| 1–3 | 10 (27%) |
| 4–5 | 25 (68%) |
| Unknown | 2 (5%) |
| Primary treatment | |
| Surgery | 28 (75%) |
| Radiotherapy | 1 (3%) |
| Systemic therapy | 8 (22%) |
| Baseline PSA (ng/mL) | 27 (IQR, 13–85) |
| Number of cycles | |
| Docetaxel | 6 (range, 4–10) |
| Cabazitaxel | 6 (range, 3–10) |
| Disease state | |
| mHSPC | 8 (22%) |
| mCRPC | 29 (78%) |
| Patients with metastasis sites | |
| Bone | 27 (73%) |
| Lymph nodes | |
| Pelvic | 16 (43%) |
| Extrapelvic | 28 (75%) |
| Prostatic bed | 7 (19%) |
| Viscera | 6 (16%) |
| Follow-up time (mo) | 23 (IQR, 15–30) |
| First PSMA PET/CT to first cycle (d) | 16 (IQR, 9–30) |
| Last cycle to second PSMA PET/CT (d) | 27 (IQR, 18–44) |
ISUP = International Society of Urological Pathology.
Qualitative data are number and percentage; continuous data are median and range or IQR.